Dr. Reddy's Laboratories (RDY) intends to sell a generic version of Novo Nordisk's (NVO) Ozempic diabetes drug following the expiry of its patent in March, several media outlets reported Wednesday, citing company officials.

The company is planning to manufacture and sell 12 million pens consisting of generic semaglutide, the active ingredient in Ozempic, in the first year after launch, according to reports.

Dr. Reddy's will collaborate with other firms in India to launch the generic product, the reports said.

The company did not immediately respond to an MT Newswires request for comment.

Price: 13.16, Change: +0.22, Percent Change: +1.66